Bear market slows PepGen's roll, causing DMD-focused biotech to price below range

Kyle LaHucik

Senior Reporter

A month after PepGen transitioned to a clinical-stage company with its Duchenne muscular dystrophy trial in Canada, the Boston biotech is debuting on Wall Street …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bear market slows PepGen's roll, causing DMD-focused biotech to price below range

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Bear mar­ket slows Pep­Gen's roll, caus­ing DMD-fo­cused biotech to price be­low range

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Bear market slows PepGen's roll, causing DMD-focused biotech to price below range